• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Dose Maintenance, Reduction With Antipsychotics

Dose Maintenance, Reduction With Antipsychotics

June 1, 2018
Adam Strassberg, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Zhou Y et al, Journal of Psychopharmacology 2018. doi:10.1177/0269881118756062

Once patients with schizophrenia are stabilized on an antipsychotic in the acute phase of their treatment, guidelines are unclear on how to continue dosing. Some guidelines recommend lowering the dose, others recommend maintaining the dose, and others give no firm recommendations whatsoever.

For fear of relapse, many clinicians never lower the dose, so many patients are simply kept on the higher acute-phase doses. These doses can be associated with more side effects, including extrapyramidal symptoms, metabolic syndrome, and impaired cognitive function.

This 52-week, single-blinded (rater-blinded), randomized controlled study sought data on maintenance and reduction using 2 frequently prescribed antipsychotics. Relapse was defined as a score of ≥ 4 on the Positive and Negative Syndrome Scale (PANSS) on at least one of the following: delusion, conceptual disorganization, hallucinatory behavior, or suspiciousness.

Researchers studied 75 stabilized schizophrenic patients, who were prescribed either risperidone (≥ 4 mg/day) or olanzapine (≥ 10 mg/day). They were randomly divided into a maintenance group (n = 38) and a dose-reduction group (n = 37).

In the maintenance group, the dose of medication remained unchanged. In the dose-reduction group, the dose of antipsychotic was reduced by 25% for the first 4 weeks, then reduced by 50% of the original dose for the remaining 48 weeks. Doses were never lowered below minimum recommendations—ie, below 2 mg/day for risperidone or below 5 mg/day for olanzapine.

Over 52 weeks, relapse rates were not significantly different between the groups, with relapse of only 4 patients in the dose-reduction group and 6 patients in the maintenance group.

A 50% dose reduction of antipsychotics did not lead to any worsening of psychotic symptoms. In fact, patients on the lower doses had fewer extrapyramidal symptoms (p = 0.012), lower body mass index (p = 0.005), improved cognitive function (p = 0.001), and improved negative symptoms overall (p < 0.001).

TCPR’s Take
Despite a small sample size, using single rather than double blinding, and being limited to only 2 antipsychotics, this study offers much-needed evidence to guide some important clinical decisions. During the maintenance phase with our stabilized schizophrenic patients, careful antipsychotic dose reduction (by 25% over the first 4 weeks, and then by 50% thereafter) is worth trying.
General Psychiatry
KEYWORDS antipsychotics research-update
    Adam Strassberg, MD.

    Can Mindfulness-Based Stress Reduction Affect Symptom Outcomes in Older Adults?

    More from this author
    www.thecarlatreport.com
    Issue Date: June 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Neurobiology, TCPR, June 2018
    A Look at the Latest Antidepressant Meta-Analysis
    Neurobiology Concepts for Psychiatrists
    The Neuroscience Behind Addictions and SSRIs
    Dose Maintenance, Reduction With Antipsychotics
    Lithium Favored in Treatment Effectiveness Study
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.